FDA approves Aimmune’s peanut allergy drug

Jan 31 (Reuters) – The U.S. Food and Drug Administration on Friday approved Aimmune Therapeutics Inc’s drug to reduce, and potentially eliminate, allergic reactions to peanuts in children aged 4 to 17.

The treatment, called AR101 and to be sold under the brand name Palforzia, was designed to gradually reduce sensitivity to peanuts by exposing patients to a highly refined version of peanut flour over the course of several months.

The drug comes with a boxed warning, FDA’s harshest type of warning.

Reporting by Carl O’Donnell; Editing by Bill Berkrot and
Shinjini Ganguli

Leave a Reply